SYLATRON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SYLATRON (SYLATRON).
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
| Metabolism | Peginterferon alfa-2b is primarily metabolized by proteolytic degradation; renal clearance contributes to elimination. |
| Excretion | Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces. |
| Half-life | Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing. |
| Protein binding | Approximately 95% bound to albumin; binding is independent of drug concentration. |
| Volume of Distribution | Mean volume of distribution is 0.99 L/kg (range 0.5-1.5 L/kg), indicating distribution primarily into extracellular fluid and tissues. |
| Bioavailability | Subcutaneous bioavailability is approximately 100% (nearly complete absorption). |
| Onset of Action | Subcutaneous administration: Induction of antiviral and antiproliferative effects begins within 24 hours, with peak serum concentrations achieved at 15-44 hours post-dose. |
| Duration of Action | Duration of action is approximately 1 week, consistent with once-weekly dosing. Clinical effects (e.g., antiviral activity, hematologic changes) persist throughout the dosing interval. |
| Molecular Weight | Approximately 31,000 Da (interferon alfa-2b) + 12,000 Da (PEG) ≈ 43,000 Da |
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
| Dosage form | VIAL |
| Renal impairment | CrCl <50 mL/min: contraindicated. No dose adjustment required for mild impairment (CrCl 50-80 mL/min) but monitor closely. End-stage renal disease (CrCl <10 mL/min): not recommended. |
| Liver impairment | Contraindicated in patients with decompensated liver disease (Child-Pugh class B or C). No formal studies in mild hepatic impairment; use with caution. |
| Pediatric use | Safety and efficacy not established in patients <18 years. Not recommended. |
| Geriatric use | No specific dose adjustment, but older patients may have decreased renal function; monitor renal function and dose accordingly. Higher incidence of adverse effects (fatigue, neuropsychiatric) reported in elderly. |
| 1st trimester | Peginterferon alfa-2b is contraindicated in pregnancy; animal studies show teratogenic effects. Avoid use in first trimester. |
| 2nd trimester | Contraindicated; may cause fetal harm. Systemic exposure should be avoided. |
| 3rd trimester | Contraindicated; risk of fetal toxicity including growth retardation and anemia. |
Clinical note
Comprehensive clinical and safety monograph for SYLATRON (SYLATRON).
| Placental transfer | Pegylated interferon alfa-2b has high molecular weight and pegylation limits transfer; however animal studies confirm embryolethality and teratogenicity, suggesting some placental transfer. Human data lacking but risk presumed. |
| Breastfeeding | Peginterferon alfa-2b is excreted in human milk; potential for adverse effects in nursing infant. Discontinue breastfeeding or drug, considering importance to mother. |
■ FDA Black Box Warning
May cause or aggravate neuropsychiatric, autoimmune, ischemic, and infectious disorders; patients should be closely monitored.
| Serious Effects |
PregnancyHypersensitivity to interferon alfa-2b or any componentAutoimmune hepatitis
| Precautions | Risk of neuropsychiatric reactions (depression, suicidality), autoimmune disorders (thyroid dysfunction, psoriasis), cardiovascular events (ischemia), pulmonary toxicity, and ophthalmologic disorders. |
| Food/Dietary | No specific food interactions. However, maintain adequate hydration to reduce risk of flu-like symptoms. Avoid grapefruit or grapefruit juice as they may affect peginterferon metabolism (theoretical; not well-studied). |
Loading safety data…
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Peginterferon alfa-2b (SYLATRON) is contraindicated in pregnancy. Based on animal studies and its mechanism of action, there is a potential for fetal harm. Interferons have abortifacient effects in primates. First trimester: high risk of miscarriage. Second and third trimesters: possible fetal growth restriction, developmental toxicity. Use effective contraception during therapy and for 10 months after last dose. |
| Fetal Monitoring | Monitor complete blood counts, liver function tests, thyroid function tests, and serum creatinine before and during therapy. Assess for depression/suicidality. Fetal monitoring by ultrasound if pregnancy occurs. Obtain pregnancy test before initiation and monthly thereafter. |
| Fertility Effects | Peginterferon alfa-2b may impair female fertility. Animal studies show prolonged estrous cycles and reduced fertility. Men may experience reversible azoospermia or oligospermia. Advise patients of potential impact on fertility. |
| Clinical Pearls |
| Sylatron (peginterferon alfa-2b) is used as adjuvant therapy for melanoma with microscopic or gross nodal involvement. Monitor for neuropsychiatric adverse effects, including depression and suicidal ideation, especially in patients with history of psychiatric disorders. Thyroid dysfunction, particularly hypothyroidism, is common; monitor TSH at baseline and periodically. Dose reductions may be necessary for severe neutropenia, thrombocytopenia, or elevated liver enzymes. Administer subcutaneously once weekly for up to 5 years, but treatment often limited by toxicity. |
| Patient Advice | Take Sylatron exactly as prescribed, once weekly by injection. · Watch for signs of depression, anxiety, or suicidal thoughts; seek immediate help if these occur. · Report any new or worsening fatigue, fever, chills, or muscle aches. · Avoid alcohol during treatment due to increased risk of liver toxicity. · Use effective contraception during and for 10 days after last dose. · Do not receive live vaccines while on Sylatron. |